Showing BioInteractions for Fostamatinib (DB12010)
BioInteractor utilizes data on drug-target, -enzyme and -transporter associations to provide insight on drug-drug interactions. It allows you to identify, for instance, which drugs act similarly on the same target. Such drugs may have additive pharmacodynamic effects if given concomitantly. Conversely, two drugs may antagonize the beneficial effects of each other by having opposite actions on a specific drug target. BioInteractor uses ranked drug-enzyme association information to predict enzyme-mediated drug interactions that may be clinically relevant.
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Adenosine receptor A3 antagonist | ||
| 1 | Adenosine receptor A3 antagonists | Aminophylline, Caffeine |
| 2 | Adenosine receptor A3 agonists | Adenosine |
| 3 | Adenosine receptor A3 inhibitors | Enprofylline |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a vesicular monoamine transporter 2 (VMAT2) inhibitor | ||
| 1 | vesicular monoamine transporter 2 (VMAT2) antagonists | Valbenazine |
| 2 | vesicular monoamine transporter 2 (VMAT2) inhibitors | Rauwolfia serpentina root |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Fatty-acid amide hydrolase 1 inhibitor | ||
| 1 | Fatty-acid amide hydrolase 1 inhibitors | Cannabidiol, Medical Cannabis, Nabiximols, Thiopental |
| 2 | Fatty-acid amide hydrolase 1 substrates | Acetaminophen, Propofol |
| 3 | Fatty-acid amide hydrolase 1 inducers | Nabiximols |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Equilibrative nucleoside transporter 1 inhibitor | ||
| 1 | Equilibrative nucleoside transporter 1 inhibitors | Cannabidiol, Medical Cannabis, Nabiximols, Troglitazone |
| 2 | Equilibrative nucleoside transporter 1 substrates | Cytarabine, Fludarabine, Fluorouracil, Gemcitabine, Mercaptopurine, Ribavirin, Tegafur-uracil, Trifluridine |
| 3 | Equilibrative nucleoside transporter 1 inducers | Pemetrexed |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a cGMP-specific 3',5'-cyclic phosphodiesterase inhibitor | ||
| 1 | cGMP-specific 3',5'-cyclic phosphodiesterase inhibitors | Avanafil, Dipyridamole, Sildenafil, Tadalafil, Theophylline, Udenafil, Vardenafil |
| 2 | cGMP-specific 3',5'-cyclic phosphodiesterase substrates | Molsidomine |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Arachidonate 5-lipoxygenase inhibitor | ||
| 1 | Arachidonate 5-lipoxygenase inhibitors | Aminosalicylic acid, Balsalazide, Cannabidiol, Diacerein, Diethylcarbamazine, Hyperforin, Masoprocol, Meclofenamic acid, Medical Cannabis, Mesalazine, Minocycline, Morniflumate, Nabiximols, Rhein, Sulfasalazine, Zileuton |
| 2 | Arachidonate 5-lipoxygenase substrates | Omega-3 fatty acids, Omega-6 fatty acids |
| 3 | Arachidonate 5-lipoxygenase antagonists | Morniflumate |
| 4 | Arachidonate 5-lipoxygenase potentiators | Diclofenac |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cathepsin S inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cathepsin L1 inhibitor | ||
| 1 | Cathepsin L1 substrates | Trastuzumab deruxtecan |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase ABL1 inhibitor | ||
| 1 | Tyrosine-protein kinase ABL1 inhibitors | ATP, Bosutinib, Brigatinib, Imatinib, Nilotinib, Ponatinib, Regorafenib |
| 2 | Tyrosine-protein kinase ABL1 antagonists | Radotinib |
| 3 | Tyrosine-protein kinase ABL1 substrates | Magnesium gluconate |
| 4 | Tyrosine-protein kinase ABL1 inducers | Magnesium gluconate |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium-dependent protein kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PknB inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ribosomal protein S6 kinase alpha-6 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Non-receptor tyrosine-protein kinase TYK2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Atypical kinase COQ8A, mitochondrial inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase JAK1 inhibitor | ||
| 1 | Tyrosine-protein kinase JAK1 inhibitors | Baricitinib, Fedratinib, Filgotinib, Pralsetinib, Ruxolitinib, Tofacitinib, Upadacitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Hepatocyte growth factor receptor inhibitor | ||
| 1 | Hepatocyte growth factor receptor antagonists | Cabozantinib |
| 2 | Hepatocyte growth factor receptor inhibitors | AMG-208, Brigatinib, Capmatinib, Crizotinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase NIM1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase MST4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a cAMP-dependent protein kinase catalytic subunit alpha inhibitor | ||
| 1 | cAMP-dependent protein kinase catalytic subunit alpha inhibitors | Ellagic acid |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 24 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Tec inhibitor | ||
| 1 | Tyrosine-protein kinase Tec inhibitors | Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase SYK inhibitor | ||
| 1 | Tyrosine-protein kinase SYK inhibitors | Ellagic acid |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 33 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 35 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 36 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 38 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 38-like inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a STE20/SPS1-related proline-alanine-rich protein kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase TAO1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase TAO2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase TAO3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase TBK1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Angiopoietin-1 receptor inhibitor | ||
| 1 | Angiopoietin-1 receptor inhibitors | Ponatinib, Regorafenib, Ripretinib, Vandetanib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity testis-specific protein kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a TGF-beta receptor type-1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a TGF-beta receptor type-2 inhibitor | ||
| 1 | TGF-beta receptor type-2 agonists | Foreskin fibroblast (neonatal), Foreskin keratinocyte (neonatal) |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase receptor Tie-1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase tousled-like 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase tousled-like 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a TRAF2 and NCK-interacting protein kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Non-receptor tyrosine-protein kinase TNK1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Activated CDC42 kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase TNNI3K inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Testis-specific serine/threonine-protein kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity protein kinase TTK inhibitor | ||
| 1 | Dual specificity protein kinase TTK inhibitors | BOS172722 |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase TXK inhibitor | ||
| 1 | Tyrosine-protein kinase TXK inhibitors | Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase receptor TYRO3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase ULK1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase ULK2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase ULK3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Wee1-like protein kinase inhibitor | ||
| 1 | Wee1-like protein kinase inhibitors | Adavosertib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Yes inhibitor | ||
| 1 | Tyrosine-protein kinase Yes inhibitors | Dasatinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 19 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase MLT inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase ZAP-70 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a AP2-associated protein kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase ABL2 inhibitor | ||
| 1 | Tyrosine-protein kinase ABL2 inhibitors | ATP |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Activin receptor type-1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Activin receptor type-1B inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Atypical kinase COQ8B, mitochondrial inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a ALK tyrosine kinase receptor inhibitor | ||
| 1 | ALK tyrosine kinase receptor inhibitors | Alectinib, Brigatinib, Crizotinib, Gilteritinib, Lorlatinib |
| 2 | ALK tyrosine kinase receptor antagonists | Ceritinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ankyrin repeat and protein kinase domain-containing protein 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Aurora kinase A inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Aurora kinase B inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Aurora kinase C inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase receptor UFO inhibitor | ||
| 1 | Tyrosine-protein kinase receptor UFO inhibitors | Gilteritinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Blk inhibitor | ||
| 1 | Tyrosine-protein kinase Blk inhibitors | Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a BMP-2-inducible protein kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Bone morphogenetic protein receptor type-1B inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Bone morphogenetic protein receptor type-2 inhibitor | ||
| 1 | Bone morphogenetic protein receptor type-2 ligands | Dibotermin alfa |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cytoplasmic tyrosine-protein kinase BMX inhibitor | ||
| 1 | Cytoplasmic tyrosine-protein kinase BMX inhibitors | Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase B-raf inhibitor | ||
| 1 | Serine/threonine-protein kinase B-raf inhibitors | Dabrafenib, Encorafenib, Regorafenib, Ripretinib, Sorafenib, Vemurafenib |
| 2 | Serine/threonine-protein kinase B-raf antagonists | Dabrafenib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase BTK inhibitor | ||
| 1 | Tyrosine-protein kinase BTK inhibitors | Abivertinib, Acalabrutinib, Ibrutinib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase type 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase type 1D inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase type 1G inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase type II subunit alpha inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase type II subunit beta inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase type II subunit delta inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase type II subunit gamma inhibitor | ||
| 1 | Calcium/calmodulin-dependent protein kinase type II subunit gamma inhibitors | Bosutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Calcium/calmodulin-dependent protein kinase kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Peripheral plasma membrane protein CASK inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Kappa-casein inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cyclin-dependent kinase 1 inhibitor | ||
| 1 | Cyclin-dependent kinase 1 inhibitors | Alsterpaullone |
| 2 | Cyclin-dependent kinase 1 binders | Indirubin-3'-monoxime, Olomoucine, SU9516 |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase MRCK gamma inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cyclin-dependent kinase 4 inhibitor | ||
| 1 | Cyclin-dependent kinase 4 inhibitors | Abemaciclib, Palbociclib, Ribociclib |
| 2 | Cyclin-dependent kinase 4 antagonists | Ribociclib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cyclin-dependent kinase-like 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cyclin-dependent kinase-like 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Chk1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Chk2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Citron Rho-interacting kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity protein kinase CLK1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity protein kinase CLK2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity protein kinase CLK3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity protein kinase CLK4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Macrophage colony-stimulating factor 1 receptor inhibitor | ||
| 1 | Macrophage colony-stimulating factor 1 receptor inhibitors | Pexidartinib, Sunitinib |
| 2 | Macrophage colony-stimulating factor 1 receptor antagonists | Imatinib |
| 3 | Macrophage colony-stimulating factor 1 receptor substrates | Erdafitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase CSK inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Casein kinase I isoform alpha inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Casein kinase II subunit alpha inhibitor | ||
| 1 | Casein kinase II subunit alpha inhibitors | Ellagic acid |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Casein kinase II subunit alpha' inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Death-associated protein kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Death-associated protein kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Death-associated protein kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase DCLK1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase DCLK2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase DCLK3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Epithelial discoidin domain-containing receptor 1 inhibitor | ||
| 1 | Epithelial discoidin domain-containing receptor 1 antagonists | Imatinib |
| 2 | Epithelial discoidin domain-containing receptor 1 inhibitors | Pralsetinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Discoidin domain-containing receptor 2 inhibitor | ||
| 1 | Discoidin domain-containing receptor 2 inhibitors | Regorafenib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity tyrosine-phosphorylation-regulated kinase 1B inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Epidermal growth factor receptor inhibitor | ||
| 1 | Epidermal growth factor receptor antagonists | Cetuximab, Erlotinib, Gefitinib, Icotinib, Lapatinib, Lidocaine, Necitumumab, Zalutumumab |
| 2 | Epidermal growth factor receptor suppressors | Panitumumab |
| 3 | Epidermal growth factor receptor inhibitors | Abivertinib, Afatinib, Brigatinib, Dacomitinib, Neratinib, Olmutinib, Osimertinib, Vandetanib, Zanubrutinib |
| 4 | Epidermal growth factor receptor agonists | Foreskin keratinocyte (neonatal) |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Eukaryotic translation initiation factor 2-alpha kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Interferon-induced, double-stranded RNA-activated protein kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a eIF-2-alpha kinase GCN2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-A receptor 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-A receptor 2 inhibitor | ||
| 1 | Ephrin type-A receptor 2 antagonists | Dasatinib |
| 2 | Ephrin type-A receptor 2 inhibitors | Regorafenib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-A receptor 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-A receptor 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-A receptor 5 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-A receptor 6 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-A receptor 7 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-A receptor 8 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-B receptor 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-B receptor 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-B receptor 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ephrin type-B receptor 6 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Receptor tyrosine-protein kinase erbB-2 inhibitor | ||
| 1 | Receptor tyrosine-protein kinase erbB-2 antagonists | Lapatinib, Margetuximab |
| 2 | Receptor tyrosine-protein kinase erbB-2 inhibitors | Afatinib, Brigatinib, Pertuzumab, Tucatinib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Receptor tyrosine-protein kinase erbB-4 inhibitor | ||
| 1 | Receptor tyrosine-protein kinase erbB-4 inhibitors | Afatinib, Brigatinib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase/endoribonuclease IRE1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Fer inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Fes/Fps inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Fibroblast growth factor receptor 1 inhibitor | ||
| 1 | Fibroblast growth factor receptor 1 agonists | Palifermin |
| 2 | Fibroblast growth factor receptor 1 inhibitors | Erdafitinib, Lenvatinib, Nintedanib, Pemigatinib, Ponatinib, Pralsetinib, Regorafenib, Selpercatinib, Sorafenib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Fibroblast growth factor receptor 2 inhibitor | ||
| 1 | Fibroblast growth factor receptor 2 agonists | Foreskin fibroblast (neonatal), Foreskin keratinocyte (neonatal), Palifermin |
| 2 | Fibroblast growth factor receptor 2 binders | Palifermin |
| 3 | Fibroblast growth factor receptor 2 antagonists | Thalidomide |
| 4 | Fibroblast growth factor receptor 2 inhibitors | Erdafitinib, Lenvatinib, Nintedanib, Pemigatinib, Ponatinib, Pralsetinib, Regorafenib, Selpercatinib |
| 5 | Fibroblast growth factor receptor 2 ligands | Sucrosofate |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Fibroblast growth factor receptor 3 inhibitor | ||
| 1 | Fibroblast growth factor receptor 3 inhibitors | Erdafitinib, Lenvatinib, Nintedanib, Pazopanib, Pemigatinib, Ponatinib, Selpercatinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Fgr inhibitor | ||
| 1 | Tyrosine-protein kinase Fgr inhibitors | Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Vascular endothelial growth factor receptor 1 inhibitor | ||
| 1 | Vascular endothelial growth factor receptor 1 inhibitors | Axitinib, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Selpercatinib, Sorafenib, Sunitinib |
| 2 | Vascular endothelial growth factor receptor 1 agonists | Foreskin fibroblast (neonatal), Polaprezinc |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Receptor-type tyrosine-protein kinase FLT3 inhibitor | ||
| 1 | Receptor-type tyrosine-protein kinase FLT3 antagonists | Midostaurin, Sorafenib |
| 2 | Receptor-type tyrosine-protein kinase FLT3 inhibitors | Brigatinib, Fedratinib, Gilteritinib, Midostaurin, Nintedanib, Pexidartinib, Ponatinib, Pralsetinib, Sunitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Vascular endothelial growth factor receptor 3 inhibitor | ||
| 1 | Vascular endothelial growth factor receptor 3 antagonists | Sorafenib |
| 2 | Vascular endothelial growth factor receptor 3 inhibitors | Axitinib, Lenvatinib, Nintedanib, Regorafenib, Selpercatinib, Sunitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase mTOR inhibitor | ||
| 1 | Serine/threonine-protein kinase mTOR ligands | Rimiducid |
| 2 | Serine/threonine-protein kinase mTOR inhibitors | Everolimus, Sirolimus, Temsirolimus |
| 3 | Serine/threonine-protein kinase mTOR potentiators | Pimecrolimus |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase FRK inhibitor | ||
| 1 | Tyrosine-protein kinase FRK inhibitors | Regorafenib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Fyn inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cyclin-G-associated kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Glycogen synthase kinase-3 alpha inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Glycogen synthase kinase-3 beta inhibitor | ||
| 1 | Glycogen synthase kinase-3 beta inhibitors | Lithium cation |
| 2 | Glycogen synthase kinase-3 beta antagonists | Tideglusib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase HCK inhibitor | ||
| 1 | Tyrosine-protein kinase HCK inhibitors | Bosutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Homeodomain-interacting protein kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Homeodomain-interacting protein kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase ICK inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Inhibitor of nuclear factor kappa-B kinase subunit beta inhibitor | ||
| 1 | Inhibitor of nuclear factor kappa-B kinase subunit beta inhibitors | Acetylcysteine, Auranofin, Mesalazine, Sulfasalazine |
| 2 | Inhibitor of nuclear factor kappa-B kinase subunit beta inducers | Arsenic trioxide |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Inhibitor of nuclear factor kappa-B kinase subunit epsilon inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Insulin receptor inhibitor | ||
| 1 | Insulin receptor agonists | Insulin aspart, Insulin detemir, Insulin glargine, Insulin glulisine, Insulin human, Insulin lispro |
| 2 | Insulin receptor binders | Insulin pork |
| 3 | Insulin receptor ligands | Insulin degludec |
| 4 | Insulin receptor activators | Chromic chloride |
| 5 | Insulin receptor bindings | Brigatinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Insulin receptor-related protein inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Interleukin-1 receptor-associated kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Interleukin-1 receptor-associated kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Interleukin-1 receptor-associated kinase 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase ITK/TSK inhibitor | ||
| 1 | Tyrosine-protein kinase ITK/TSK inhibitors | Pazopanib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase JAK2 inhibitor | ||
| 1 | Tyrosine-protein kinase JAK2 inhibitors | Baricitinib, Entrectinib, Fedratinib, Pralsetinib, Ruxolitinib, Tofacitinib, Zanubrutinib |
| 2 | Tyrosine-protein kinase JAK2 antagonists | Tofacitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase JAK3 inhibitor | ||
| 1 | Tyrosine-protein kinase JAK3 inhibitors | Baricitinib, Tofacitinib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Vascular endothelial growth factor receptor 2 inhibitor | ||
| 1 | Vascular endothelial growth factor receptor 2 antagonists | Cabozantinib, Midostaurin, Ramucirumab, Sorafenib |
| 2 | Vascular endothelial growth factor receptor 2 inhibitors | Axitinib, Lenvatinib, Midostaurin, Nintedanib, Pazopanib, Ponatinib, Pralsetinib, Regorafenib, Ripretinib, Sunitinib |
| 3 | Vascular endothelial growth factor receptor 2 substrates | Erdafitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase SIK3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mast/stem cell growth factor receptor Kit inhibitor | ||
| 1 | Mast/stem cell growth factor receptor Kit antagonists | Dasatinib, Imatinib, Midostaurin, Nilotinib, Sorafenib |
| 2 | Mast/stem cell growth factor receptor Kit inhibitors | Avapritinib, Lenvatinib, Midostaurin, Pazopanib, Pexidartinib, Ponatinib, Regorafenib, Ripretinib, Sunitinib |
| 3 | Mast/stem cell growth factor receptor Kit agonists | Ancestim |
| 4 | Mast/stem cell growth factor receptor Kit substrates | Erdafitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase LATS1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Lck inhibitor | ||
| 1 | Tyrosine-protein kinase Lck inhibitors | Nintedanib, Ponatinib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a LIM domain kinase 1 inhibitor | ||
| 1 | LIM domain kinase 1 antagonists | Dabrafenib |
| 2 | LIM domain kinase 1 inhibitors | Dabrafenib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a LIM domain kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Leucine-rich repeat serine/threonine-protein kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Leukocyte tyrosine kinase receptor inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Lyn inhibitor | ||
| 1 | Tyrosine-protein kinase Lyn inhibitors | Nintedanib, Ponatinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | ||
| 1 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitors | Binimetinib, Bosutinib, Selumetinib, Trametinib |
| 2 | Dual specificity mitogen-activated protein kinase kinase 2 antagonists | Trametinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity mitogen-activated protein kinase kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity mitogen-activated protein kinase kinase 5 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Dual specificity mitogen-activated protein kinase kinase 6 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 1 inhibitor | ||
| 1 | Mitogen-activated protein kinase kinase kinase 1 inhibitors | Binimetinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 10 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 11 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 12 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 13 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 15 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 2 inhibitor | ||
| 1 | Mitogen-activated protein kinase kinase kinase 2 inhibitors | Bosutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 6 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase 9 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase kinase 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase kinase kinase kinase 5 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase 10 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase 13 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase 14 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase 15 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase 7 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Mitogen-activated protein kinase 9 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a MAP kinase-activated protein kinase 5 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase MARK1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase MARK2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a MAP/microtubule affinity-regulating kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a MAP/microtubule affinity-regulating kinase 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a CLIP-associating protein 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Microtubule-associated serine/threonine-protein kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Megakaryocyte-associated tyrosine-protein kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Maternal embryonic leucine zipper kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Mer inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Misshapen-like kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a MAP kinase-interacting serine/threonine-protein kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a MAP kinase-interacting serine/threonine-protein kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Macrophage-stimulating protein receptor inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Muscle, skeletal receptor tyrosine-protein kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Myosin light chain kinase, smooth muscle inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Myosin light chain kinase 2, skeletal/cardiac muscle inhibitor | ||
| 1 | Myosin light chain kinase 2, skeletal/cardiac muscle inhibitors | Prenylamine |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Myosin light chain kinase 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Myosin light chain kinase family member 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Myosin-IIIa inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Nek1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Nek11 inhibitor | ||
| 1 | Serine/threonine-protein kinase Nek11 antagonists | Dabrafenib |
| 2 | Serine/threonine-protein kinase Nek11 inhibitors | Dabrafenib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Nek2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Nek3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Nek4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Nek5 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Nek9 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a High affinity nerve growth factor receptor inhibitor | ||
| 1 | High affinity nerve growth factor receptor antagonists | Imatinib |
| 2 | High affinity nerve growth factor receptor agonists | Amitriptyline |
| 3 | High affinity nerve growth factor receptor activators | Amitriptyline |
| 4 | High affinity nerve growth factor receptor inhibitors | Entrectinib, Larotrectinib, Pralsetinib, Regorafenib |
| 5 | High affinity nerve growth factor receptor stimulators | Cenegermin |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a BDNF/NT-3 growth factors receptor inhibitor | ||
| 1 | BDNF/NT-3 growth factors receptor agonists | Amitriptyline |
| 2 | BDNF/NT-3 growth factors receptor inhibitors | Entrectinib, Larotrectinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a NT-3 growth factor receptor inhibitor | ||
| 1 | NT-3 growth factor receptor inhibitors | Entrectinib, Larotrectinib, Pralsetinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a NUAK family SNF1-like kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a NUAK family SNF1-like kinase 2 inhibitor | ||
| 1 | NUAK family SNF1-like kinase 2 activators | Bempedoic acid |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase OSR1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PAK 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PAK 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PAK 3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PAK 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PAK 6 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PAK 5 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cyclin-dependent kinase 16 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cyclin-dependent kinase 17 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Platelet-derived growth factor receptor alpha inhibitor | ||
| 1 | Platelet-derived growth factor receptor alpha inhibitors | Lenvatinib, Midostaurin, Nintedanib, Pazopanib, Ponatinib, Regorafenib, Ripretinib, Sunitinib |
| 2 | Platelet-derived growth factor receptor alpha antagonists | Imatinib, Midostaurin, Olaratumab |
| 3 | Platelet-derived growth factor receptor alpha agonists | Foreskin keratinocyte (neonatal) |
| 4 | Platelet-derived growth factor receptor alpha substrates | Erdafitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Platelet-derived growth factor receptor beta inhibitor | ||
| 1 | Platelet-derived growth factor receptor beta antagonists | Dasatinib, Imatinib, Midostaurin, Sorafenib, Trapidil |
| 2 | Platelet-derived growth factor receptor beta inhibitors | Midostaurin, Nintedanib, Pazopanib, Pexidartinib, Pralsetinib, Regorafenib, Ripretinib, Sunitinib |
| 3 | Platelet-derived growth factor receptor beta agonists | Foreskin fibroblast (neonatal), Polaprezinc |
| 4 | Platelet-derived growth factor receptor beta substrates | Erdafitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a 3-phosphoinositide-dependent protein kinase 1 inhibitor | ||
| 1 | 3-phosphoinositide-dependent protein kinase 1 inhibitors | Celecoxib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Cyclin-dependent kinase 15 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Phosphatidylinositol 4-kinase beta inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform inhibitor | ||
| 1 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform inhibitors | Caffeine, Copanlisib, Duvelisib, Idelalisib, TG100-115 |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform inhibitor | ||
| 1 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform inhibitors | Duvelisib, TG100-115 |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase pim-1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase pim-3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Phosphatidylinositol 5-phosphate 4-kinase type-2 beta inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase N1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase N2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PLK1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PLK2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PLK3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PLK4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a 5'-AMP-activated protein kinase catalytic subunit alpha-1 inhibitor | ||
| 1 | 5'-AMP-activated protein kinase catalytic subunit alpha-1 activators | Adenosine phosphate, Phenformin |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a 5'-AMP-activated protein kinase inhibitor | ||
| 1 | 5'-AMP-activated protein kinase activators | Acetylsalicylic acid, Adenosine phosphate |
| 2 | 5'-AMP-activated protein kinase inducers | Topiramate |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a cAMP-dependent protein kinase catalytic subunit beta inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Protein kinase C delta type inhibitor | ||
| 1 | Protein kinase C delta type ligands | Ingenol mebutate |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Protein kinase C epsilon type inhibitor | ||
| 1 | Protein kinase C epsilon type activators | Bryostatin 1 |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Protein kinase C gamma type (PRKCG) inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Protein kinase C iota type inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Protein kinase C theta type inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase D1 inhibitor | ||
| 1 | Serine/threonine-protein kinase D1 activators | Bryostatin 1 |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a cGMP-dependent protein kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase PRP4 homolog inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Focal adhesion kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Protein-tyrosine kinase 2-beta inhibitor | ||
| 1 | Protein-tyrosine kinase 2-beta antagonists | Leflunomide |
| 2 | Protein-tyrosine kinase 2-beta inhibitors | Baricitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Protein-tyrosine kinase 6 inhibitor | ||
| 1 | Protein-tyrosine kinase 6 inhibitors | Vandetanib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a RAF proto-oncogene serine/threonine-protein kinase inhibitor | ||
| 1 | RAF proto-oncogene serine/threonine-protein kinase inhibitors | Dabrafenib, Regorafenib, Sorafenib |
| 2 | RAF proto-oncogene serine/threonine-protein kinase antagonists | Dabrafenib |
| 3 | RAF proto-oncogene serine/threonine-protein kinase agonists | Cholecystokinin |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Proto-oncogene tyrosine-protein kinase receptor Ret inhibitor | ||
| 1 | Proto-oncogene tyrosine-protein kinase receptor Ret antagonists | Cabozantinib |
| 2 | Proto-oncogene tyrosine-protein kinase receptor Ret inhibitors | Lenvatinib, Ponatinib, Pralsetinib, Regorafenib, Selpercatinib, Sorafenib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase RIO1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase RIO2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase RIO3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Receptor-interacting serine/threonine-protein kinase 1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Receptor-interacting serine/threonine-protein kinase 2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Receptor-interacting serine/threonine-protein kinase 4 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Rho-associated protein kinase 2 inhibitor | ||
| 1 | Rho-associated protein kinase 2 inhibitors | Netarsudil, Ripasudil |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Proto-oncogene tyrosine-protein kinase ROS inhibitor | ||
| 1 | Proto-oncogene tyrosine-protein kinase ROS inhibitors | Entrectinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ribosomal protein S6 kinase alpha-1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Ribosomal protein S6 kinase alpha-3 inhibitor | ||
| 1 | Ribosomal protein S6 kinase alpha-3 inhibitors | Acetylsalicylic acid |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase SBK1 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Uncharacterized serine/threonine-protein kinase SBK3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase Sgk3 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase SIK1 inhibitor | ||
| 1 | Serine/threonine-protein kinase SIK1 antagonists | Dabrafenib |
| 2 | Serine/threonine-protein kinase SIK1 inhibitors | Dabrafenib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase SIK2 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a STE20-like serine/threonine-protein kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a SNF-related serine/threonine-protein kinase inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Proto-oncogene tyrosine-protein kinase Src inhibitor | ||
| 1 | Proto-oncogene tyrosine-protein kinase Src inhibitors | Bosutinib, Nintedanib, Ponatinib, Tirbanibulin |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Tyrosine-protein kinase Srms inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 10 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 16 inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 17A inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 17B inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a Serine/threonine-protein kinase 32A inhibitor | ||
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Fostamatinib is a ATP-binding cassette sub-family B member 5 substrate | ||
| 1 | ATP-binding cassette sub-family B member 5 substrates | Amrubicin, Baloxavir marboxil, Bilastine, Brentuximab vedotin, Brigatinib, Dasabuvir, Delafloxacin, Naldemedine, Vinflunine |
| 2 | ATP-binding cassette sub-family B member 5 inhibitors | Bilastine, Brigatinib, Dofequidar, Lofexidine |
| 3 | ATP-binding cassette sub-family B member 5 inducers | Doxycycline |